Related Experiment Video
Updated: Jun 8, 2026
12:40
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Aurora kinase inhibitors as anticancer molecules.
Hiroshi Katayama1, Subrata Sen
1Department of Molecular Pathology, Unit 951, The University of Texas M.D. Anderson Cancer Center, 7435 Fannin, Houston, TX 77054, USA.
Biochimica Et Biophysica Acta
|September 25, 2010
Summary
Aurora kinases A and B are key regulators of cell division, often overexpressed in cancers. Inhibitors targeting these kinases show promise as anticancer therapies by correcting chromosomal instability and related pathways.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Aurora kinases (A, B, and C) are serine/threonine kinases crucial for mitosis.
- Aurora-A and Aurora-B are highly expressed in somatic cells and implicated in cancer development, including chromosomal instability.
- Aberrant Aurora kinase expression disrupts tumor suppressor and oncoprotein pathways.
Purpose of the Study:
- To discuss the functional roles of Aurora kinase-A and -B in cancer-related cellular phenotypes.
- To review findings on Aurora kinase inhibitors and their mechanisms.
- To explore future directions for next-generation Aurora kinase inhibitors in cancer therapy.
Main Methods:
- Literature review of Aurora kinase function in mitosis and cancer.
- Analysis of preclinical and clinical trial data for Aurora kinase inhibitors.
- Discussion of molecular mechanisms of Aurora kinase regulation and inhibition.
Main Results:
- Aurora kinases A and B are vital for mitotic regulation and their dysregulation contributes to oncogenesis.
- Multiple Aurora kinase inhibitors have demonstrated encouraging results in preclinical studies and early-phase clinical trials.
- Inhibitors modulate Aurora kinase interactions, impacting cancer-associated pathways.
Conclusions:
- Aurora kinase inhibitors represent a promising targeted therapy for various cancers.
- Further development of next-generation inhibitors is warranted to enhance clinical utility.
- Targeting Aurora kinases offers a strategic approach to combatting cancer-related chromosomal instability and pathway derangements.
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...